期刊文献+

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Patients with Chronic Hepatitis C Receiving a Personalized Treatment Program 被引量:2

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Patients with Chronic Hepatitis C Receiving a Personalized Treatment Program
下载PDF
导出
摘要 To investigate the effects of individualised treatment with peginterferon alpha-2a(40 kD)plus ribavirin in Chinese patients with CHC.Methods Total of 297 consecutive Chinese patients were enrolled,including 250 nave cases and 47 cases who were previously treated.Treatment duration was determined according to viral genotypes,prior treatment history and viral responses at week 4,12 and 24.Results Totally,235 patients(79.1%)completed treatment and 186(87.3%)achieved SVR.And 219 out of 289(75.8%)patients achieved HCV RNA negative at week 4(RVR)and 259 of 276(93.8%)at week 12.Among the 164 patients with RVR who completed follow-up,158(96.3%)achieved SVR.Patients with RVR had lower baseline viral loads than patients without RVR(P=0.034).The positive predictive value(PPV)of RVR for SVR was 90.7%(OR 2.10 vs.non-RVR,95%CI:0.50-8.7).Similar outcomes were observed among patients with HCV undetectable at week 12.Conclusions Viral suppression by week 4 is associated with a high rate of treatment success in treatment nave and experienced patients receiving individualized CHC therapy. To investigate the effects of individualised treatment with peginterferon alpha-2a(40 kD)plus ribavirin in Chinese patients with CHC.Methods Total of 297 consecutive Chinese patients were enrolled,including 250 nave cases and 47 cases who were previously treated.Treatment duration was determined according to viral genotypes,prior treatment history and viral responses at week 4,12 and 24.Results Totally,235 patients(79.1%)completed treatment and 186(87.3%)achieved SVR.And 219 out of 289(75.8%)patients achieved HCV RNA negative at week 4(RVR)and 259 of 276(93.8%)at week 12.Among the 164 patients with RVR who completed follow-up,158(96.3%)achieved SVR.Patients with RVR had lower baseline viral loads than patients without RVR(P=0.034).The positive predictive value(PPV)of RVR for SVR was 90.7%(OR 2.10 vs.non-RVR,95%CI:0.50-8.7).Similar outcomes were observed among patients with HCV undetectable at week 12.Conclusions Viral suppression by week 4 is associated with a high rate of treatment success in treatment nave and experienced patients receiving individualized CHC therapy.
出处 《国际感染病学(电子版)》 CAS 2013年第2期60-70,共11页 Infection International(Electronic Edition)
基金 funded by Shanghai Roche Pharmaceuticals Ltd.
关键词 Chronic hepatitis C Early viral kinetics Pegylated interferon RIBAVIRIN Sustained virological response Tailored regimen Chronic hepatitis C Early viral kinetics Pegylated interferon Ribavirin Sustained virological response Tailored regimen
  • 相关文献

参考文献2

二级参考文献18

  • 1杜绍财,陶其敏.丙型肝炎病毒基因5‘—末端非编码区酶切分型研究[J].中华医学杂志,1993,73(1):7-9. 被引量:45
  • 2孙南雄.-[J].实用肝脏病杂志,1998,3(1):58-58.
  • 3张永祥.-[J].国外医学流行病学与传染病学分册,1998,25(2):53-53.
  • 4黄祖瑚.-[J].南京医学院学报,1994,14(1):43-43.
  • 5张永祥,国外医学.流行病学、传染病学分册,1998年,25卷,2期,53页
  • 6孙南雄,实用肝脏病杂志,1998年,3卷,1期,58页
  • 7黄祖瑚,南京医学院学报,1994年,14卷,1期,43页
  • 8Dr. Akihito Tsubota MD,Hiromitsu Kumada MD,Kazuaki Chayama MD,Yasuji Arase MD,Satoshi Saitoh MD,Isao Koida MD,Naoya Murashima MD,Yoshiyuki Suzuki MD,Masahiro Kobayashi MD,Kimiko Takagi BSc,Mariko Kobayashi BSc,Kenji Ikeda MD.Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections[J].Digestive Diseases and Sciences.1996(10)
  • 9Shiffman ML,Suter F,Bacon BR,Nelson D,Harley H,Sola R,Shafran SD,Barange K,Lin A,Soman A,Zeuzem S.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[].The New England Journal of Medicine.2007
  • 10Dalgard O,Bjoro K,Ring-Larsen H,Bjornsson E,Holberg- Petersen M,Skovlund E,Reichard O,Myrvang B,Sundelof B,Ritland S,Hellum K,Fryden A,Florholmen J,Verbaan H.Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response[].Hepatology.2008

共引文献46

同被引文献14

引证文献2

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部